BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That M...
April 03 2020 - 1:10PM
- Introduction to ViralClear management and scientific
team
- Strategy for rapid FDA advancement of
Vicromax(tm)
- Update on BioSig core business developments and
commercialization plans
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing a
proprietary biomedical signal processing platform, today announced
that it intends to provide a public business update via
teleconference regarding its recently acquired anti-viral
pharmaceutical candidate, Vicromax(tm). The briefing is being held
on Tuesday, April 7, 2020 at 11am ET.
ViralClear Pharmaceuticals, Inc. will be represented by Nick
Spring, CEO, Steven King, COO and Jerome Zeldis, M.D., Ph.D,
Executive Chair. BioSig will be represented by Kenneth L. Londoner,
MBA, Chairman and CEO of BioSig Technologies, Inc.
Conference Call Details:Date:
Tuesday, April 7, 2020 Time: 11:00 A.M. Eastern
Time (ET) Dial in Number for U.S. Callers: 1-
877-407-8293 Dial in Number for International
Callers: 1- 201-689-8349
A replay will be available for two weeks starting on April 7,
2020 at approximately 2:00 P.M. ET. To access the replay, please
dial 1- 877-660-6853 in the U.S. and 1- 201-612-7415 for
international callers. The conference ID# is 13701652.
In a preliminary internal review, the orally administered,
broad-spectrum anti-viral agent Vicromax(tm) demonstrated strong
activity against COVID-19 in cell cultures in laboratory testing.
In this analysis, Vicromax(tm) was added to a tissue culture assay
for SARS-CO-2 coronavirus (the causative agent for COVID-19) and an
anti-viral effect was observed, which led to a reduction of over
90% of infectious viruses. The Company intends to pursue
development of this agent for the treatment of COVID-19 through
FDA-approved clinical trials.
The product candidate already completed Phase I and three Phase
II clinical trials involving over 134 subjects for indications
other than COVID-19, and underwent extensive animal testing and
human clinical experience. The Company expects that Vicromax(tm)
might be used alone or in a combination with other anti-viral
agents or immune modulators.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (ii) difficulties in
obtaining financing on commercially reasonable terms; (iii) changes
in the size and nature of our competition; (iv) loss of one or more
key executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024